University of Colorado School of Medicine and The Children's Hospital, Denver, Colorado, USA.
Int J Antimicrob Agents. 1993 Feb;2(2):97-103. doi: 10.1016/0924-8579(93)90047-9.
It is now apparent that neutralizing antibody may play an important role in ameliorating RSV lower repiratory tract illness. At the present time immunoprophylaxis and immunotherapy with polyclonal antibodies show the most promise in the prevention and treatment of RSV illness. Several questions remained to be answered. These include the practical application of IGIV in prevention and treatment of RSV illness. Intravenous lines are often difficult to place and maintain. With the further development of polyclonal or monoclonal antibodies it may be possible to immunize prospective donors and boost their anti RSV titers to the degree that a hyper-immune IGIV with sufficient antibody to be given intramuscularly could be produced. The role for RSV-specific monoclonal antibodies for disease prevention or treatment must be defined as well as the appropriatee viral epitopes to target. In the absence of a safe and effective vaccine, it is clear that, despite these questions passive immunotherapy and immunoprophylaxis offers the greatest hope for the prevention and treatment of RSV disease in high risk infants and children.
现在很明显，中和抗体可能在减轻 RSV 下呼吸道疾病方面发挥重要作用。目前，使用多克隆抗体进行免疫预防和免疫治疗在 RSV 疾病的预防和治疗方面最有希望。仍有一些问题需要回答。这些问题包括 IGIV 在 RSV 疾病预防和治疗中的实际应用。静脉通路往往难以放置和维持。随着多克隆或单克隆抗体的进一步发展，有可能对预期的供体进行免疫接种，并将其抗 RSV 滴度提高到足以产生具有足够抗体可肌肉内给药的高免疫 IGIV 的程度。需要确定 RSV 特异性单克隆抗体在疾病预防或治疗中的作用，以及适当的病毒表位。在没有安全有效的疫苗的情况下，很明显，尽管存在这些问题，但被动免疫疗法和免疫预防为预防和治疗高危婴儿和儿童的 RSV 疾病提供了最大的希望。
